Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema cardiovascular outcomes trial in participants with established cardiovascular disease
NL-OMON55925Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- Apr 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of cagrilintide and semaglutide in cardiac morbidity (2 arms), sponsored by Novo Nordisk. Started Apr 2023; status: recruiting.
02
Drugs
cagrilintidesemaglutide
03
Conditions
cardiac morbidity
Beyond the preview
Go deeper on NL-OMON55925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55925.